Tumor necrosis factor-alpha (TNF-α) inhibitors are a cornerstone in the management of chronic immune-mediated diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis [1], and, in selected cases, refractory sarcoidosis [2]. Here, TNF is linked to ankylosing spondylitis.